secwatch.observer — SEC 8-K summary
======================================

Issuer:     Guardant Health, Inc. (GH)
CIK:        0001576280
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001576280-24-000108
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Guardant Health Q1 revenue up 31% to $168.5M; raises 2024 revenue guidance to $675-685M
--------------------------------------------------------------------------------

- Revenue $168.5M (+31% YoY); net loss narrowed to $115M ($0.94 loss per share) from $133.5M.
- Precision oncology revenue $156.2M (+38%); clinical tests +20%, biopharma tests +37%.
- 2024 revenue guidance raised to $675-685M (prior $655-670M); FCF guidance improved to $(275)-$(285)M.
- Non-GAAP gross margin ex-screening guided to 61%-63% (prior 60%-62%).
- ECLIPSE published in NEJM; FDA Advisory Committee on May 23; Shield IVD launch expected post-approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1576280/000157628024000108/0001576280-24-000108-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1576280/000157628024000108/gh-20240509.htm
  HTML page:      https://secwatch.observer/filing/0001576280-24-000108

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer